BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 15770489)

  • 1. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
    Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
    Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
    Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed.
    Erazo Valle A; Wisniewski T; Figueroa Vadillo JI; Burke TA; Martinez Corona R
    Curr Med Res Opin; 2006 Dec; 22(12):2403-10. PubMed ID: 17257454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study.
    Naito Y; Kai Y; Ishikawa T; Fujita T; Uehara K; Doihara H; Tokunaga S; Shimokawa M; Ito Y; Saeki T
    Breast Cancer; 2020 Jan; 27(1):122-128. PubMed ID: 31407150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.
    Escobar Y; Cajaraville G; Virizuela JA; Álvarez R; Muñoz A; Olariaga O; Tamés MJ; Muros B; Lecumberri MJ; Feliu J; Martínez P; Adansa JC; Martínez MJ; López R; Blasco A; Gascón P; Calvo V; Luna P; Montalar J; Del Barrio P; Tornamira MV
    Support Care Cancer; 2015 Sep; 23(9):2833-40. PubMed ID: 26081597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
    Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
    Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan.
    Mizuno M; Hiura M; Kikkawa F; Numa F; Yaegashi N; Narahara H; Aoki D; Kimura E; Kato H; Shimokawa M; Sugiyama T; Kamura T
    Gynecol Oncol; 2016 Mar; 140(3):559-64. PubMed ID: 26748216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R; O'Boyle E; Cooper W
    BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.
    Lee MA; Cho EK; Oh SY; Ahn JB; Lee JY; Thomas B; Jung H; Kim JG
    Cancer Res Treat; 2016 Oct; 48(4):1420-1428. PubMed ID: 26875197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
    Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
    Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
    Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
    Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
    Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
    Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
    Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
    Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
    Ng WL; Della-Fiorentina SA
    Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.